Biological Properties of Dialysable Peptides Derived from Plasmin Digestion of Bovine Fibrinogen Preparations

Summary

Dialysable peptides (M. W. less than 12,000) were obtained by plasmin digests of purified bovine fibrinogen. The biological effects of these peptides were studied in rats in three different test systems: ADP-induced platelet aggregation, isolated atria contractility and vascular permeability.

The effects induced by the peptides were: inhibition of ADP-induced platelet aggregation, increase in the frequency of isolated atria contractions and local increase in vascular permeability. All these activities were concentration dependent. Six micrograms of the peptides were still effective in increasing vascular permeability; in the in vitro systems the smallest effective dose ranged between 165 and 650 μg/ml.

Following elution through a Sephadex G-25 gel with bidistilled water, four fractions were obtained. The second fraction (M.W. about 5,000) was the most active, followed by the first and then the third one; the fourth fraction was inactive.

These data suggest that local accumulation of peptides in vivo may be of clinical relevancy.

^* Visiting Scientist from the Department of Pharmacology, Medical School, Bialystok, Poland Reprint requests to Dr. G. de Gaetano.

• References

• 1 Babulova A, Bareggi S. R, Bonaccorsi A, Garattini S, Morselli P. L, Pantarotto C. 1973; Correlation between desipramine levels and (–)-noradrenaline uptake and chronotropic effect in isolated atria of rats. British Journal of Pharmacology 48: 464.
• 2 Born D. V. R. 1962; Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927.
• 3 Buczko W, Wiśniewski K. 1972; Studies on the role of fibrinolysis and fibrinogen degradation products (FDP) in analgesic action of morphine. Thrombosis et Diathesis Haemorrhagica 28: 359.
• 4 Buczko W, Wiśniewski K, Malinowska L. 1973; Effect of fibrinogen degradation products (FDP) on the action of certain centrally acting drugs. Thrombosis Research 2: 219.
• 5 Buluk K, Malofiejew M. 1969; The pharmacological properties of fibrinogen degradation products. British Journal of Pharmacology 35: 79.
• 6 Culasso D. E, Donati M. B, de Gaetano G, Vermylen J, Verstraete M. 1974; Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations: role of contaminating factor VIII-related material. Blood 44: 169.
• 7 Itzhaki R. F, Gill D. M. 1964; A micro-biuret method for estimating proteins. Analytical Biochemistry 9: 401.
• 8 Malofiejew M. 1971; The biological and pharmacological properties of some fibrinogen degradation products. Scandinavian Journal of Haematology Suppl 13: 303.
• 9 Marder V. J, Budzyński A. Z, Solum N. O, Sevy R, Rigollot C. 1973. A quantitative study of physiologic effects of peptides derived from human fibrinogen by plasmin digestion. In: Peeters H. (ed.) Protides of the biological fluids-20th. Colloquium, Pergamon Press; Oxford: 295.
• 10 Solum N. O, Rigollot C, Budzynski A. Z, Marder V. J. 1973; A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. British Journal of Haematology 24: 419.
• 11 Stachurska J, Latallo Z, Kopeć M. 1970; Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP). Thrombosis et Diathesis Haemorrhagica 23: 91.
• 12 Udaka K, Takeuchi Y, Movat H. Z. 1973; Simple method for quantitation of enhanced vascular permeability. Proceedings of the Society for Experimental Biology and Medicine 133: 1384.
• 13 Wiśniewski K, Tarasiewicz S, Mackowiak J, Buczko W. Moniuszko-Jakoniuk 1974; The effects of trypsin digested globulin degradation products (TDPG) on the activity of central nervous system. Pharmacology (Basel) 12: 321.